Chloramphenicol succinate

Chloramphenicol succinate is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC₅₀ of 1.585 nM. Chloramphenicol succinate serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate exerts a significant inhibitory effect on colitis. Chloramphenicol succinate can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease^[1][2][3]. In Vitro:Chloramphenicol succinate (50 μM; 3-24 h) is slowly oxidized to Chloramphenicol by cultured human bone marrow monocytes within 24 h^[1].
Chloramphenicol succinate (50-100 μM; 30-60 min) is oxidized to Chloramphenicol by mitochondria isolated from human liver, rat liver and rat kidney within 60 min^[1].
Chloramphenicol succinate is hydrolyzed by esterases present in the liver, kidney and lung of humans and animals, but not by blood esterases^[2].
Chloramphenicol succinate ((0.01-100 μM; 24 h) exhibits only extremely low cytotoxicity against HT-29 cells when incubated at concentrations up to 100 μM for 24 h^[3]. In Vivo:Chloramphenicol succinate (50-100 μM; administered rectally; once daily for 7 consecutive days) significantly alleviates DSS (HY-116282C)-induced colitis in mice^[3].